Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
60 hedge funds and large institutions have $392M invested in Aerie Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 8 closing their positions.
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
31% more capital invested
Capital invested by funds: $299M → $392M (+$93.7M)
13% more funds holding
Funds holding: 53 → 60 (+7)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$15.8M |
| 2 |
DM
Deerfield Management
New York
|
+$13.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$9.4M |
| 4 |
Goldman Sachs
New York
|
+$5.36M |
| 5 |
CNB
City National Bank
Beverly Hills,
Delaware
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IHM
Iguana Healthcare Management
New York
|
-$1.11M |
| 2 |
ARC
Absolute Return Capital
Boston,
Massachusetts
|
-$1.05M |
| 3 |
IMS
Index Management Solutions
Philadelphia,
Pennsylvania
|
-$655K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$633K |
| 5 |
Jennison Associates
New York
|
-$456K |
AERI Hedge Fund Activity: Q2 2014 in Review
60 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q2 2014, worth a combined $392M — up 31% from $299M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new AERI positions and 8 closed out — a net gain of 7 holders — while 26 added to existing stakes and 14 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $15.8M. The largest seller was Iguana Healthcare Management, cutting an estimated $1.11M.
- 60 institutional investors held Aerie Pharmaceuticals (AERI) as of Q2 2014, up from 53 in Q1 2014.
- Funds reported $392M of Aerie Pharmaceuticals stock for Q2 2014, up 31% quarter-over-quarter.
- 15 funds opened new Aerie Pharmaceuticals positions in Q2 2014 and 8 closed out, a net change of +7 holders.
- The largest Aerie Pharmaceuticals buyer in Q2 2014 was Perceptive Advisors, an estimated $15.8M added.
- The largest Aerie Pharmaceuticals seller in Q2 2014 was Iguana Healthcare Management, an estimated $1.11M sold.
Based on aggregated 13F filings for Q2 2014.